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Abstract
Background: For a diploid organism such as human, the two alleles of a particular gene can be
expressed at different levels due to X chromosome inactivation, gene imprinting, different local
promoter activity, or mRNA stability. Recently, imbalanced allelic expression was found to be
common in human and can follow Mendelian inheritance. Here we present a method that employs
real competitive PCR for allele-specific expression analysis.
Results: A transcribed mutation such as a single nucleotide polymorphism (SNP) is used as the
marker for allele-specific expression analysis. A synthetic mutation created in the competitor is
close to a natural mutation site in the cDNA sequence. PCR is used to amplify the two cDNA
sequences from the two alleles and the competitor. A base extension reaction with a mixture of
ddNTPs/dNTP is used to generate three oligonucleotides for the two cDNAs and the competitor.
The three products are identified and their ratios are calculated based on their peak areas in the
MALDI-TOF mass spectrum. Several examples are given to illustrate how allele-specific gene
expression can be applied in different biological studies.
Conclusions: This technique can quantify the absolute expression level of each individual allele of
a gene with high precision and throughput.
Background
Mutations in the human genome can cause biochemical
changes in protein products, or mRNA expression levels
[1]. Epigenetic modifications such as DNA methylation
can also change gene expression. Abnormal methylation
is frequently detected in cancer (for review, see [2]).
Allele-specific expression of heterozygotic genes (either a
mutant allele or a wild type allele is expressed at a higher
level than the other allele) might be one reason that carri-
ers have different disease manifestations. Recently, Lo and
colleagues showed that allelic variation in gene expression
is common in the human genome [3]. Out of the 602 het-
erozygous genes surveyed in the kidney and lung tissues
from seven individuals, 326 (54%) showed preferential
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expression of one allele in at least one individual. Bray
and colleagues showed that skewed allelic expression in
the human brain occurs due to cis-acting variations [4]. In
addition, Yan and colleagues found that allelic variation
of gene expression can follow Mendelian inheritance [5].
Fluorescent dideoxy terminators and capillary gel electro-
phoresis [5], microarrays (Affymetrix HuSNP oligo
arrays), real time PCR [3] and polymerase colonies [6]
have been used for allele-specific expression. However,
direct analysis of allelic expression has been limited for
technological reasons. For example, capillary gel electro-
phoresis sometimes has difficulty detecting and quantify-
ing extension products from the two different alleles. Real
time PCR, when used for allele-specific detections,
requires substantial optimization so that the two alleles
can have sufficient annealing temperature difference. The
technical difficulties have caused experimental inconsist-
encies such as debates over whether APOE ε 3/4 brain
mRNA shows allele-specific expression [7,8].
Here we present a method that employs real competitive
PCR [9] for allele-specific expression analysis. Real com-
petitive PCR combines competitive PCR, primer extension
reaction and matrix-assisted laser desorption/ionization –
time of flight mass spectrometry (MALDI-TOF MS). Real
competitive PCR can be used for high-throughput
(>7,000 reactions/day using one mass spectrometer),
absolute quantification of RNA transcripts with high pre-
cision (coefficient of variation < 10% with no assay opti-
mization). To distinguish the two transcripts of a gene
from the two alleles, transcribed single nucleotide poly-
morphisms (SNPs) or rare disease mutations in carriers
are used as markers. MALDI-TOF MS can distinguish two
oligonucleotides (in the 4000–9000 Da range) with
molecular weight difference as small as a few Da, and thus
can unambiguously detect the two alleles and the compet-
itor. This technique can be used to quantify simultane-
ously the absolute expression level of each individual
allele of a gene with high precision and throughput.
Results and Discussion
Recently, matrix-assisted laser desorption ionization –
time of flight mass spectrometry (MALDI-TOF MS) was
adapted for quantitative gene expression analysis [9]. This
technique, dubbed as real competitive PCR, combines
competitive PCR, primer extension reaction and MALDI-
TOF MS. After isolation of RNA and reverse transcription,
cDNA is spiked with a synthetic oligonucleotide (the com-
petitor) with an identical sequence except one single base
roughly in the middle of the sequence to the cDNA of
interest. The competitor and the cDNA of interest are co-
amplified by PCR. Excess dNTPs are removed by shrimp
alkaline phosphatase treatment after PCR. Then, a base
extension reaction is carried out with an extension primer,
a combination of three different ddNTPs and one dNTP
and a ThermoSequenase. The base extension primer
hybridizes right next to the mutation site and either one
or two bases are added for the competitor and the cDNA,
yielding two oligonucleotide products with different
molecular weights (typically around 300 Da difference).
In a typical molecular weight window of 4,000 to 9,000
Da, MALDI-TOF MS can easily distinguish two oligonu-
cleotides if they differ by more than 10 Da. These two
extension products are thus readily identified, and the
ratio of their concentrations is quantified by MALDI-TOF
MS.
As shown in Figure 1, when the synthetic mutation cre-
ated in the competitor is close to a natural mutation site
in the cDNA sequence, real competitive PCR can be used
for accurate allele-specific gene expression analysis. PCR is
used to amplify the two cDNA sequences from the two
alleles and the competitor. A base extension reaction with
a mixture of three different ddNTPs and one dNTP is used
to generate three (instead of two in a typical real compet-
itive PCR experiment) oligonucleotides for the two
cDNAs and the competitor. The three products are identi-
fied and their ratios are calculated based on their peak
areas in the mass spectrum.
Since the amount of competitor spiked in is known, the
absolute concentration of each of the two cDNAs can be
easily calculated. Thus, it is possible to simultaneously
quantify the gene expression levels from the two alleles of
one gene. The competitor and the two cDNAs are virtually
identical in sequence and are amplified with the same
kinetics. The allele specificity is superior due to the high
precision of MALDI-TOF MS in molecular weight
determination.
One example of allele-specific expression analysis by real
competitive PCR is shown in Figure 2A. A single nucle-
otide polymorphism (refSNP ID: rs2069849) located in
exon 2 of the interleukin 6 gene is selected as the marker
for allele-specific expression. Complementary DNA
(0.025 ng) prepared from the IMR-90 cell line (ATCC)
was co-amplified with 5 × 10-22 Mol (301 copies) of the
competitor. The oligonucleotide products from the base
extension reaction were analyzed by MALDI-TOF MS. The
peak area ratios represent accurately the concentration
ratios of the two cDNAs and the competitor. Coefficient of
variations (CV is defined as standard deviation divided by
the mean) for the relative frequencies of the three peaks
were 9.2%, 4.1% and 4.4% for four real competitive PCR
replicates, indicating excellent precision. The interleukin 6
gene also shows modest skewing in allelic expression (98
copies of C allele was expressed, and 136 copies of T allele
was expressed, see Figure 2A).BMC Genetics 2004, 5 http://www.biomedcentral.com/1471-2156/5/8
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Schematic view of quantitative and allele-specific expression analysis with real competitive PCR Figure 1
Schematic view of quantitative and allele-specific expression analysis with real competitive PCR. A point muta-
tion in the cDNA sequence is used as the marker for allele-specific gene expression analysis. The competitor is designed to 
have a synthetic mutation next to the natural mutation and is used for quantitative gene expression analysis. Three extension 
products from the two cDNA sequences and the competitor have different molecular weights, and are detected by MALDI-
TOF MS. The peak area ratios of these products represent accurately the concentration ratios of the two cDNAs and the 
competitor. Since the absolute quantity of the competitor is known, the absolute quantities of the two cDNA sequences can 
be readily calculated.BMC Genetics 2004, 5 http://www.biomedcentral.com/1471-2156/5/8
Page 4 of 6
(page number not for citation purposes)
We next tested allele-specific expression of the lexA gene in
Escherichia coli. Gene expression perturbation in E. coli was
used for gene network studies [10]. Expression perturba-
tion was achieved by introducing an exogenous copy for
Mass spectra for allele-specific expression analysis Figure 2
Mass spectra for allele-specific expression analysis. (A) Interleukin 6 gene. Peaks are identified by C, T and S. C repre-
sents the allele where the polymorphic site has a C residue. T represents the allele where the polymorphic site has a T residue. 
S represents the competitor. The peak areas of C, T and S peaks are automatically computed by the RT software package 
(SEQUENOM). The peak area ratios represent the concentration ratios of the starting cDNA sequences and the competitor. 
The peak frequencies are 0.209, 0.263 and 0.528 for peak C, T and S, respectively. (B) lexA gene. Peak S, G and C represent the 
competitor, the exogenous and the endogenous lexA gene, respectively. Without arabinose induction, only endogenous lexA 
gene expression was seen. With modest arabinose induction, both the endogenous and exogenous lexA gene expression were 
seen. Without induction, the peak frequencies are 0.601, 0.004 and 0.395 for peak S, G and C, respectively. With induction, 
the peak frequencies are 0.509, 0.075 and 0.416 for peak S, G and C, respectively. (C) ABCD-1 gene. Mut and WT represent 
mutant and wild type alleles, respectively. For Q672X, the peak frequencies are 0.984 and 0.016 for peak Mut and WT, respec-
tively. For S213C, the peak frequencies are 0.187 and 0.813 for peak Mut and WT, respectively. For S108W, the peak frequen-
cies are 0.995 and 0.005 for peak WT and Mut, respectively.BMC Genetics 2004, 5 http://www.biomedcentral.com/1471-2156/5/8
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each gene of interest in an inducible expression plasmid.
The expression of each gene potentially in a gene
regulatory network was perturbed via the induction of the
exogenous gene expression, and the expression changes of
other genes were analyzed. These perturbed gene expres-
sion levels were then fed into a multiple linear regression
algorithm to estimate the network interactions. This
approach appears to be a powerful tool for functional
genomics analysis. However, self-regulatory interactions
such as positive and negative self-feedbacks can only be
resolved by measuring the exogenous and endogenous
gene expression separately. In the original study on the E.
coli network, a reporter gene (luciferase), expressed under
identical conditions as the gene of interest, was used to
estimate the exogenous gene expression. However, this
estimate is likely to be inaccurate since the expression
level of the luciferase gene is likely to be different from the
exogenous genes, even when they are under the control of
the same promoter. If we can directly and separately quan-
tify the expressions of the exogenous and the endogenous
gene, we will be able to obtain significantly more accurate
estimates of self-regulatory interactions in gene networks.
To this end, an exogenous lexA was introduced into E. coli
via the pBADX53 vector. The exogenous lexA gene is dis-
tinguishable from the endogenous lexA gene by a silent
mutation (TCC to TCG silent mutation at codon 103).
The exogenous lexA expression was induced with arab-
inose. Without arabinose, only endogenous lexA  tran-
script was detected (Figure 2B). With an intermediate
arabinose induction, exogenous lexA  was expressed at
about 20% level compared with the endogenous lexA
(Figure 2B).
In the third example, we tested allele-specific expression
of the ABCD-1  gene (located on the X chromosome)
involved in X-linked adrenoleukodystrophy (XALD). The
manifestation of symptoms in XALD carriers was previ-
ously shown to be associated with a higher degree of non-
random X chromosome inactivation [11]. A non-random
X chromosome inactivation is likely to cause a preferential
expression down-regulation of one of the ABCD-1 allele.
If the wild type allele is inactivated, the mutant allele will
be predominantly expressed. Thus, the individual might
show symptoms similar to a homozygous mutant. X chro-
mosome inactivation studies can only provide a genome-
wide, indirect picture while direct allele-specific gene
expression can provide the direct link between gene
expression and disease manifestation. We thus carried out
allele-specific gene expression for three carriers with three
different  ABCD-1  mutations (S108W, S213C and
Q672X). The S108W carrier showed predominant (>99%)
mutant allele expression while the S213C and Q672X
showed predominant wild type allele (89% and >99%,
respectively) expression (Figure 2C). This result is in com-
plete concordance with results obtained previously [11].
Conclusions
We present here a straightforward method for quantitative
and allele-specific gene expression analysis with real com-
petitive PCR. The allele specificity for gene expression
analysis is based on the superior molecular weight deter-
mination ability of the MALDI-TOF MS technology.
Highly precise (CV 4% – 9%) and absolute gene expres-
sion analysis is achieved. In addition, the real competitive
PCR is based on the highly automated MassARRAY system
(SEQUENOM), and is ideal for high-throughput (7000
reactions/day/instrument) analysis. The high-throughput
and low cost features of this technique can easily be
exploited in large-scale allele-specific expression studies.
Methods
cDNA and oligonucleotides
Interleukin 6 gene expression analysis
Complementary DNA for interleukin 6 gene expression
analysis was prepared from cell line IMR-90 (ATCC). The
PCR primer sequences for the interleukin 6 gene expres-
sion analysis are, 5'-ACGTTGGATGGCAGGACAT-
GACAACTCATC-3' and 5'-
ACGTTGGATGCCATGCTACATTTGCCGAAG-3'. The
extension primer sequence is 5'-CGCAGCTTTAAG-
GAGTT-3'. The synthetic competitor sequence is 5'-
GCCCATGCTACATTTGCCGAAGAGCCCTCAGGCTGGA
CTGCATAAACTCCTTAAAGCTGCGCAGAATGAGAT-
GAGTTGTCATGTCCTGCAG-3'. All oligonucleotides were
purchased from Integrated DNA Technologies (Coralville,
IA). The synthetic competitor was PAGE purified by the
vendor and absorbance at 260 nm was measured in our
laboratory.
lexA gene expression analysis
RNA samples for lexA gene expression analysis were pro-
vided by Dr. Timothy Gardner (Boston University). The
exogenous lexA gene has a TCC to TCG silent mutation at
codon 103 so that it can be distinguished from the endog-
enous lexA gene. The exogenous lexA gene was cloned in
the vector pBADX53. Bacterial culture and RNA extraction
were carried out as previously described [10]. The PCR
primer sequences for the lexA gene expression analysis are,
5'-ACGTTGGATGGCGCAACAGCATATTGAAGG-3' and
5'-ACGTTGGATGACATCCCGCTGACGCGCAGC-3'. The
extension primer sequence is 5'-ATCAGCATTCGGCTT-
GAATA-3'. The synthetic competitor sequence is 5'-
ACATCCCGCTGACGCGCAGCAGGAAATCAGCATTCGG
CTTGAATATGGAAGGATCGACCTGATAATGACCT-
TCAATATGCTGTTGCGC-3'. The synthetic competitor
was PAGE purified by the vendor and absorbance at 260
nm was measured in our laboratory.
ABCD-1 gene expression analysis
Complementary DNA and genomic DNA samples for
ABCD-1  gene expression analysis were prepared asBMC Genetics 2004, 5 http://www.biomedcentral.com/1471-2156/5/8
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previously described [11]. Three ABCD-1 carriers, S108W,
S213C and Q672X, were used in this study. PCR primers
for the three mutations are: 5'-ACGTTGGATGAGCAGCT-
GCCAGCCAAAAGC-3' and 5'-ACGTTGGATGACTCG-
GCCGCCTTGGTGAG-3' for S108W, 5'-
ACGTTGGATGTAGGAAGTCACAGCCACGTC-3' and 5'-
ACGTTGGATGAACCCTGACCAGTCTCTGAC-3' for
S213C, and 5'-ACGTTGGATGTCCCTGTGGAAATAC-
CACAC-3' and 5'-ACGTTGGATGAGTCCAGCTTCTC-
GAACTTC-3' for Q672X. The extension primers are: 5'-
GGCGGGCCACATACACC-3' for S108W, 5'-AGTGGCTT-
GGTCAGGTTG-3' for S213C and 5'-AATAC-
CACACACACTTGCTA-3' for Q672X.
Real competitive PCR
Real competitive PCR was carried out as was previously
described [9].
Step 1: PCR amplification
Each PCR reaction contains 1 µL diluted cDNA (0.025 ng/
µL), 0.5 µL 10× HotStar Taq PCR buffer, 0.2 µL MgCl2 (25
mM), 0.04 µL dNTP mix (25 mM each), 0.02 µL HotStar
Taq Polymerase (50 U/µL, Qiagen), 0.1 µL competitor oli-
gonucleotide (5 × 10-9 µM), 1 µL forward and reverse
primer (1 µM each) and 2.14 µL ddH2O. The PCR condi-
tion was: 95°C for 15 min for hot start, followed by
denaturing at 94°C for 20 sec, annealing at 56°C for 30
sec and extension at 72°C for 1 min for 45 cycles, and
finally incubated at 72°C for 3 min.
Step 2: Shrimp alkaline phosphatase treatment
PCR products were treated with shrimp alkaline phos-
phatase to remove excess dNTPs. A mixture of 0.17 µL
hME buffer (SEQUENOM), 0.3 µL shrimp alkaline phos-
phatase (SEQUENOM) and 1.53 µL ddH2O was added to
each PCR reaction. The reaction solutions (now 7 µL
each) were incubated at 37°C for 20 min, followed by
85°C for 5 min to inactive the enzyme.
Step 3: Single base extension reaction
For each base extension reaction, 0.2 µL of selected
ddNTPs/dNTP mixture (SEQUENOM), 0.108 µL of
selected extension primer, 0.018 µL of ThermoSequenase
(32 U/µL, SEQUENOM) and 1.674 µL ddH2O were
added. The base extension condition was, 94°C for 2 min,
followed by 94°C for 5 sec, 52°C for 5 sec and 72°C for
5 sec for 40 cycles. The ddNTPs/dNTP mixtures are:
ddATP/ddCTP/ddGTP/dTTP for interleukin 6 and ABCD-
1  Q672X, ddTTP/ddCTP/ddGTP/dATP for lexA, and
ddATP/ddCTP/ddTTP/dGTP for ABCD-1  S108W and
S213C.
Step 4: Liquid dispensing and MALDI-TOF MS
The final base extension products were treated with Spec-
troCLEAN (SEQUENOM) resin to remove salts in the
reaction buffer. This step was carried out with a Multimek
(Beckman) 96 channel auto-pipette and 16 µL resin/water
solution was added into each base extension reaction,
making the total volume 25 µL. After a quick centrifuga-
tion (2,500 rpm, 3 min) in a Sorvall legend RT centrifuge,
approximately 10 nL of reaction solution was dispensed
onto a 384 format SpectroCHIP (SEQUENOM) pre-spot-
ted with a matrix of 3-hydroxypicolinic acid (3-HPA) by
using a MassARRAY Nanodispenser (SEQUENOM). A
modified Bruker Biflex MALDI-TOF mass spectrometer
was used for data acquisitions from the SpectroCHIP.
Mass spectrometric data were automatically imported into
the SpectroTYPER (SEQUENOM) database for automatic
analysis such as noise normalization and peak area
analysis.
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